ANGIOMAX RTU

Peak

bivalirudin

NDAINTRAVENOUSSOLUTION
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

Thrombin Inhibitors

Pharmacologic Class:

Anti-coagulant

Clinical Trials (2)

NCT02052635Phase 4Terminated

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Started Sep 2014
34 enrolled
Non-ST Elevation Acute Coronary Syndrome
NCT00464087Phase 3Completed

Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI

Started Jun 2007
100 enrolled
Acute Coronary Syndromes

Loss of Exclusivity

LOE Date
May 20, 2039
160 months away
Patent Expiry
May 20, 2039

Patent Records (4)

Patent #ExpiryTypeUse Code
11903993
May 20, 2039
U-3817
11918622
May 20, 2039
U-3817
11992514
May 20, 2039
Product
12472224
May 20, 2039
Product
U-3817